Royalty Pharma to Present at Cowen's 42nd Annual Health Care Conference

Rhea-AI Summary

Royalty Pharma (Nasdaq: RPRX) will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 8, 2022, at 11:10 a.m. ET. The event will be accessible via the company's Events page and archived for thirty days. Royalty Pharma is a leader in biopharmaceutical royalties, collaborating with various innovators and entitling itself to payments from top-selling therapies. Its portfolio includes royalties on over 35 products, enhancing funding for innovation in the biopharmaceutical sector.

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at Cowen’s 42^nd Annual Health Care Conference on March 8, 2022 at 11:10 a.m. ET.

The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events. The webcast will also be archived for a minimum of thirty days.

About Royalty Pharma

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson’s Imbruvica, Johnson & Johnsons’ Tremfya, Astellas’ and Pfizer’s Xtandi, Biogen’s Tysabri, Johnson & Johnson’s Tremfya, Gilead’s Trodelvy, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and ten development-stage product candidates. For more information, visit www.royaltypharma.com.

Royalty Pharma Investor Relations and Communications

+1 (212) 883-6772
ir@royaltypharma.com

 

FAQ

When is Royalty Pharma's participation in Cowen’s Health Care Conference?

Royalty Pharma is scheduled to participate in Cowen’s 42nd Annual Health Care Conference on March 8, 2022, at 11:10 a.m. ET.

Where can I watch Royalty Pharma's fireside chat?

The webcast of Royalty Pharma's fireside chat will be available on their Events page and can be accessed for thirty days after the event.

What is Royalty Pharma's role in the biopharmaceutical industry?

Royalty Pharma is the largest buyer of biopharmaceutical royalties and funds innovation through partnerships and acquisitions of royalties.

How many commercial products are in Royalty Pharma's portfolio?

Royalty Pharma's portfolio includes royalties on more than 35 commercial products.

What types of companies does Royalty Pharma collaborate with?

Royalty Pharma collaborates with academic institutions, research hospitals, non-profits, and various biotechnology and pharmaceutical companies.